Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 479

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 9A
Chunk 479
---
 incentive plans

        3,513

        —

        —

        Common stock issuable under the Company's      convertible debt

        9,287

        —

        —

        Weighted-average common shares outstanding, diluted

        107,875

        92,398

        87,559

        Earnings (loss) per common share, basic
         
        $
        2.47

        $
        (5.80
        )
         
        $
        (8.03
        )

        Earnings (loss) per common share, diluted
         
        $
        2.34

        $
        (5.80
        )
         
        $
        (8.03
        )

F-38

The following table summarizes potential shares of common stock that were excluded from the computation of diluted earnings per share as they were anti-dilutive:

        For the Year Ended December 31,

        2024

        2023

        2022

        (in thousands)

        Common stock issuable under the Company's equity incentive plans

        2,520
         
        (1)
         
        11,956
         
        (2)
         
        11,229
         
        (3)

        Common stock issuable under the Company's convertible debt

        —

        9,542

        13,813

        Total number of potentially issuable common stock

        2,520

        21,498

        25,042

       (1) As of December 31, 2024, the anti-dilutive common stock issuable under the Company's equity incentive plans excludes 1.2 million shares that are dilutive but have performance or market conditions that were not met as of the end of the period.(2) As of December 31, 2023, the anti-dilutive common stock issuable under the Company's equity incentive plans includes 1.1 million shares that have performance or market conditions that were not met. These were anti-dilutive as the Company was in a net loss position at the end of the period.(3) As of December 31, 2022, the anti-dilutive common stock issuable under the Company's equity incentive plans includes 1.1 million shares that have performance or market conditions that were not met. These were anti-dilutive as the Company was in a net loss position